当前位置： SCI文献检索 > INTERNATIONAL JOURNAL OF CARDIOLOGY期刊下所有文献 > Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.

Abstract：

OBJECTIVE:To identify factors associated with troponin elevation and to measure the effect of elevated troponin on survival in cancer patients participating in phase I trials. METHODS:Clinical characteristics, cardiovascular risk factors, and biological data from consecutive patients treated in phase I trials (January 2010-November 2012) were reviewed. Troponin value was measured for each patient before study-drug administration and then weekly. Cardiac troponin I was considered elevated if >0.06ng/mL. Incidence and relative risk of elevated troponin adjusted for potential confounding factors were estimated using multivariable Poisson regression models. A conditional Cox proportional hazards model was used to compare overall survival in patients with elevated troponin matched to patients without troponin elevation recruited in the same trial. RESULTS:Of 463 patients, 42 (9%) experienced ≥1 episode of troponin I elevation after a median of 5weeks (interquartile range: 3-13) from drug initiation. Crude incidence of troponin elevation was 36/1000 person-months (95% confidence interval [CI]: 25-47). Troponin elevation was more frequent in patients exposed to antiangiogenic compounds versus other treatments (relative risk: 1.9, 95% CI: 1.1-3.3). Median overall survival from drug initiation was 9months (95% CI: 8-10), and 8months (95% CI: 2-13) in patients with troponin elevation. In the case-control analysis, risk of death was higher in patients with troponin elevation (hazard ratio: 2.9, 95% CI: 1.2-6.8). CONCLUSION:Patients exposed to antiangiogenic compounds had a higher risk of troponin elevation, which was associated with a higher risk of death.

journal_name

Int J Cardiol

journal_title

International journal of cardiology

authors

Hollebecque A,Lanoy E,Troallen F,Soulat-Dufour L,Massard C,Bahleda R,Varga A,Gazzah A,Postel-Vinay S,Ribrag V,Deutsch E,Angevin E,Boccara F,Cohen A,Soria JC,Ederhy S

doi

10.1016/j.ijcard.2016.04.010

subject

Has Abstract

pub_date

2016-07-01 00:00:00

pages

364-9

eissn

0167-5273

issn

1874-1754

pii

S0167-5273(16)30685-4

journal_volume

214

pub_type

杂志文章

在线工具

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.